SwedenBIO regularly examines the life science industry landscape. We measure the status of the sector annually in our Life Science Barometer. Every three years, we map the Swedish pharmaceutical projects in the Pipeline Report. We also publish special reports on selected areas such as financing, precision medicine and more.
The Life Science Barometer 2024
The Life Science Barometer 2024 offers a snapshot of the Swedish Life Science industry.
The 2024 report in high resolution PDF
The 2024 report in reduced size PDF
Regional outbreaks based on the 2024 Barometer
- Uppsala region: Insight Magazine – Uppsala’s Life Science sector
- Skåne region: Life Science Barometer 2024 – Skåne Edition
- Stockholm region: coming in May
- Gothenburg region: coming in June
The Swedish Drug Discovery and Development Pipeline Report
The 2023 pipeline report shows that 159 Swedish R&D pharma and biotech companies are actively developing new drugs.
The homepage of the 2023 report
The appendix of the 2023 report in PDF
Archive – Swedish Drug Discovery and Development Pipeline
2020 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
Industry standard for fundraising in life sciences
SwedenBIO’s recommendation for information disclosure for life science companies in the development phase.
Financing activities in the Life Sciences sector
An analysis of 361 financing events from 46 companies during the period 2007-2018.
Special focus on Rare Diseases
This paper, published together with Business Sweden, describes the orphan disease pipeline of Swedish companies and presents statistics over orphan drug designations granted by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Precision Medicine – the Swedish Industry Guide 2018
A first mapping of the Swedish precision medicine industry landscape. It is a guide to 76 companies, all of which are developing innovative products and services with the potential of advancing the field. At the end of the report, there is a listing of their relevant R&D projects as well as launched products.
Fact sheet
The factsheets provide practical information and advice from other members.
In partnership with Kickfile/Devicia/Clarvin/Morris Law (January 2021)
White paper – medical device software
In cooperation with Nasdaq (November 2020)
In collaboration with Valea (March 2019)
In collaboration with Recall Capital (February 2019)
Creating sustainable trading on the stock market – tips for small companies
In collaboration with NDA Group (June 2018)
Regulatory authorities contribute to successful drug development
In collaboration with Groth & Co (April 2018)
In collaboration with Paues Åberg Communications (March 2018)
